India’s Biocon to sell branded formulations business to Eris Lifesciences for $150 million
BENGALURU (Reuters) -Biopharmaceutical company Biocon’s unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences in a deal worth 12.42 billion rupees ($150 million), the companies said in separate exchange filings on Thursday. The deal, which is expected to close by April 15, 2024, includes the acquisition of insulin brands Basalog and …








